株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

放射性医薬品市場:放射性同位元素、エンドユーザー、ソース、用途別 - 世界の業界分析、規模、シェア、成長、動向、予測

Radiopharmaceutical Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2024

発行 Transparency Market Research 商品コード 405950
出版日 ページ情報 英文 183 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.24円で換算しております。
Back to Top
放射性医薬品市場:放射性同位元素、エンドユーザー、ソース、用途別 - 世界の業界分析、規模、シェア、成長、動向、予測 Radiopharmaceutical Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2024
出版日: 2018年05月03日 ページ情報: 英文 183 Pages
概要

当レポートでは、世界の放射性医薬品市場について調査し、市場の現状と将来見通し、放射性同位元素別、エンドユーザー別、ソース別、用途別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 序論

第2章 仮定と調査方法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
  • 概要
  • 主な市場指標
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会
  • 市場分析と予測
    • 市場価値予測
    • 市場収益予測
  • 市場分析と予測
  • ポーターズファイブフォース分析
  • バリューチェーン分析
  • 市場見通し
  • 放射性医薬品の用途

第5章 放射性同位元素別市場分析と予測

  • イントロダクションと定義
  • 主な調査結果と動向
  • 主な動向
  • 放射性同位元素別市場価値予測
    • テクネチウム99
    • ガリウム67
    • ヨード123
    • ヨード125
    • 18F
    • ルビジウム82
    • イットリウム99
    • ルテチウム177
    • その他
  • 比較マトリクス
  • 放射性同位元素別市場の魅力度

第6章 ソース別市場分析と予測

  • イントロダクションと定義
  • 主な調査結果と動向
  • 主な動向
  • 市場価値分析予測
    • 原子炉
    • サイクロトロン
  • 比較マトリクス
  • ソース別市場の魅力度

第7章 用途別市場分析と予測

  • イントロダクションと定義
  • 主な調査結果と動向
  • 主な動向
  • 市場価値分析予測
    • 心臓
    • 消化器
    • 腫瘍
    • 腎臓
    • 神経
    • 免疫
  • 比較マトリクス
  • 用途別市場の魅力度

第8章 エンドユーザー別市場分析と予測

  • イントロダクションと定義
  • 主な調査結果と動向
  • 主な動向
  • 市場価値シェア分析
    • 病院
    • 外来外科センター
    • 診断センター
    • 癌研究機関
    • その他
  • 比較マトリクス
  • エンドユーザー別市場の魅力度

第9章 地域別市場分析

  • 主な調査結果
  • 政策と法規制
  • 地域別市場価値予測
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 地域別市場の魅力度

第10章 北米市場

第11章 欧州市場

第12章 アジア太平洋地域市場

第13章 ラテンアメリカ市場

第14章 中東・アフリカ市場

第15章 競合環境

  • 主要企業:競合ダッシュボード
  • 市場シェア分析
  • 企業プロファイル
    • Advanced Accelerator Applications (AAA)
    • Bayer AG
    • Eckert & Ziegler
    • GE Healthcare
    • IBA Radiopharma Solutions
    • Lantheus Holdings, Inc.
    • Mallinckrodt plc.
    • Nordion, Inc.
    • Positron Corporation
    • Siemens Healthineers

図表

図表

List of Tables

  • Table 1: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014-2024
  • Table 2: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 3: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 4: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014-2024
  • Table 5: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014-2024
  • Table 6: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Region, 2014-2024
  • Table 7: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, By Country, 2014-2024
  • Table 8: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014-2024
  • Table 9: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 10: North America Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 11: North America Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Oncology Application, 2014-2024
  • Table 12: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014-2024
  • Table 13: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014-2024
  • Table 14: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014-2024
  • Table 15: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 16: Europe Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 17: Europe Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Oncology Application, 2014-2024
  • Table 18: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014-2024
  • Table 19: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014-2024
  • Table 20: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014-2024
  • Table 21: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 22: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 23: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014-2024
  • Table 24: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014-2024
  • Table 25: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014-2024
  • Table 26: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014-2024
  • Table 27: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 28: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 29: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014-2024
  • Table 30: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014-2024
  • Table 31: Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014-2024
  • Table 32: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014-2024
  • Table 33: Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 34: Middle East and Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 35: Middle East and Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014-2024
  • Table 36: Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014-2024

List of Figures

  • FIG. 1 Global Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014-2024
  • FIG. 3 Market Value Share, by Source (2016)
  • FIG. 5 Market Value Share, by End-user (2016)
  • FIG. 2 Market Value Share, by Radioisotope (2016)
  • FIG. 4 Market Value Share, by Application (2016)
  • FIG. 6 Global Radiopharmaceutical Market Value Share Analysis, by Radioisotope, 2016 and 2024
  • FIG. 7 Global Technetium-99 Market Revenue
  • FIG. 8 Global Gallium-67 Market Revenue
  • FIG. 9 Global Iodine-123 Market Revenue
  • FIG. 10 Global 18F Market Revenue (US$ Mn),
  • FIG. 11 Global Rubidium-82 Market Revenue
  • FIG. 12 Global Yttrium-90 Market Revenue (US$ Mn), 2014-2024
  • FIG. 13 Global Lutetium-177 Market Revenue
  • FIG. 14 Global Iodine-125 Market Revenue (US$ Mn), 2014-2024
  • FIG. 15 Global Other Radioisotope Market Revenue (US$ Mn), 2014-2024
  • FIG. 16 Global Radiopharmaceutical Market Attractiveness Analysis, by Radioisotope, 2016-2024
  • FIG. 17 Global Radiopharmaceutical Market Value Share Analysis, by Source, 2016 and 2024
  • FIG. 18 Global Nuclear Reactor Market Revenue
  • FIG. 19 Global Cyclotrons Market Revenue (US$ Mn), 2014-2024
  • FIG. 20 Global Radiopharmaceutical Market Attractiveness Analysis, by Source 2016 and 2024
  • FIG. 21 Global Radiopharmaceutical Market Value Share Analysis, by Application, 2016 and 2024
  • FIG. 22 Global Radiopharmaceutical Market Value Share Analysis, by Oncology Application, 2016 and 2024
  • FIG. 23 Global Cardiology Market Revenue
  • FIG. 24 Global Gastroenterology Market Revenue
  • FIG. 25 Global Oncology Market Revenue
  • FIG. 26 Global Nephrology Market Revenue (US$ Mn),
  • FIG. 27 Global Neurology Market Revenue
  • FIG. 28 Global Immunology Market Revenue (US$ Mn), 2014-2024
  • FIG. 29 Global Others Market Revenue (US$ Mn), 2014-2024
  • FIG. 30 Global Brachytherapy Market Revenue
  • FIG. 31 Global Others Market Revenue (US$ Mn), 2014-2024
  • FIG. 32 Global Radiopharmaceutical Market Attractiveness Analysis, by Application, 2016-2024
  • FIG. 33 Global Radiopharmaceutical Market Value Share Analysis, by End-user, 2016 and 2024
  • FIG. 34 Global Hospitals Market Revenue (US$ Mn), 2014-2024
  • FIG. 35 Global Ambulatory Surgical Center Market Revenue (US$ Mn), 2014-2024
  • FIG. 36 Global Diagnostic Centers Market Revenue
  • FIG. 37 Global Others Market Revenue (US$ Mn),
  • FIG. 38 Global Other End user Market Revenue
  • FIG. 39 Global Radiopharmaceutical Market Attractiveness Analysis, by End-user, 2016-2024
  • FIG. 40 Global Radiopharmaceutical Market Value Share Analysis, by Region, 2016 and 2024
  • FIG. 41 Global Radiopharmaceutical Market Attractiveness Analysis, by Region, 2016-2024
  • FIG. 42 North America Radiopharmaceutical Market Size
  • FIG. 43 North America Market Attractiveness Analysis,
  • FIG. 44 North America Market Value Share Analysis By Country, 2016 and 2024
  • FIG. 45 North America Market Value Share Analysis Source, 2016 and 2024
  • FIG. 46 North America Market Value Share Analysis by Source, 2016 and 2024
  • FIG. 47 North America Radiopharmaceuticals Market Value Share Analysis, by Application, 2016 and 2024
  • FIG. 48 North America Radiopharmaceuticals Market Value Share Analysis, by Oncology Application, 2016 and 2024
  • FIG. 49 North America Market Value Share Analysis by End-user, 2016 and 2024
  • FIG. 50 North America Market Attractiveness Analysis by Radioisotope, 2016-2024
  • FIG. 51 North America Market Attractiveness Analysis by Source, 2016-2024
  • FIG. 52 North America Market Attractiveness Analysis by Application, 2016-2024
  • FIG. 53 North America Market Attractiveness Analysis by End -user, 2016-2024
  • FIG. 54 Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014-2024
  • FIG. 55 Europe Market Attractiveness Analysis, by Country, 2016-2024
  • FIG. 56 Europe Market Value Share Analysis, by Country, 2016 and 2024
  • FIG. 57 Europe Market Value Share Analysis, by Radioisotope, 2016 and 2024
  • FIG. 58 Europe Market Value Share Analysis, by Source, 2016 and 2024
  • FIG. 59 Europe Radiopharmaceuticals Market Value Share Analysis, by Application, 2016 and 2024
  • FIG. 60 Europe Radiopharmaceuticals Market Value Share Analysis, by Oncology Application, 2016 and 2024
  • FIG. 61 Europe Market Value Share Analysis, by End-user, 2016 and 2024
  • FIG. 62 North America Market Attractiveness Analysis by Radioisotope, 2016-2024
  • FIG. 63 North America Market Attractiveness Analysis by Source, 2016-2024
  • FIG. 64 North America Market Attractiveness Analysis by Application, 2016-2024
  • FIG. 65 North America Market Attractiveness Analysis by End -user, 2016-2024
  • FIG. 66 Asia Pacific Radiopharmaceutical Market Size
  • FIG. 67 Asia Pacific Radiopharmaceutical Market Attractiveness Analysis, by Country, 2016-2024
  • FIG. 68 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by Country, 2016 and 2024
  • FIG. 69 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by Radioisotope, 2016 and 2024
  • FIG. 70 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by Source, 2016 and 2024
  • FIG. 71 Asia Pacific Market Value Share Analysis, by Application, 2016 and 2024
  • FIG. 72 Asia Pacific Market Value Share Analysis, by Oncology Application, 2016 and 2024
  • FIG. 73 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by End-user, 2016 and 2024
  • FIG. 74 Asia Pacific Market Attractiveness Analysis by Radioisotope, 2016-2024
  • FIG. 75 Asia Pacific Market Attractiveness Analysis by Source, 2016-2024
  • FIG. 76 Asia Pacific Market Attractiveness Analysis by Application, 2016-2024
  • FIG. 77 Asia Pacific Market Attractiveness Analysis by End -user, 2016-2024
  • FIG. 78 Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014-2024
  • FIG. 79 Latin America Market Attractiveness Analysis, by Country, 2016-2024
  • FIG. 80 Latin America Radiopharmaceutical Market Value Share Analysis, by Country, 2016 and 2024
  • FIG. 81 Latin America Market Value Share Analysis, by Radioisotope, 2016 and 2024
  • FIG. 82 Latin America Market Value Share Analysis, by Source, 2016 and 2024
  • FIG. 83 Latin America Market Value Share Analysis, by Application, 2016 and 2024
  • FIG. 84 Latin America Market Value Share Analysis, by Oncology Application, 2016 and 2024
  • FIG. 85 Latin America Market Value Share Analysis, by End-user, 2016 and 2024
  • FIG. 86 Latin America Market Attractiveness Analysis by Radioisotope, 2016-2024
  • FIG. 87 Latin America Market Attractiveness Analysis by Source, 2016-2024
  • FIG. 88 Latin America Market Attractiveness Analysis by Application, 2016-2024
  • FIG. 89 Latin America Market Attractiveness Analysis by End -user, 2016-2024
  • FIG. 90 Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014-2024
  • FIG. 91 Middle East & Africa Radiopharmaceutical Market Attractiveness Analysis, by Country, 2016-2024
  • FIG. 92 Middle East & Africa Radiopharmaceutical Market Value Share Analysis, by Country, 2016 and 2024
  • FIG. 93 Middle East & Africa Radiopharmaceutical Market Value Share Analysis, by Radioisotope, 2016 and 2024
  • FIG. 94 Middle East & Africa Market Value Share Analysis,
  • FIG. 95 Middle East and Africa Market Value Share Analysis, by Application, 2016 and 2024
  • FIG. 96 Middle East and Africa Market Value Share Analysis, by Oncology Application, 2016 and 2024
  • FIG. 97 Middle East & Africa Radiopharmaceutical Market Value Share Analysis, by End-user, 2016 and 2024
  • FIG. 98 Middle East and Africa Market Attractiveness Analysis by Radioisotope, 2016-2024
  • FIG. 99 Middle East and Africa Market Attractiveness Analysis by Source, 2016-2024
  • FIG. 100 Middle East and Africa Market Attractiveness Analysis by Application, 2016-2024
  • FIG. 101 Middle East and Africa Market Attractiveness Analysis by End -user, 2016-2024
  • FIG. 102 Global Radiopharmaceutical Market Share Analysis, by Company (2015)
目次

Radiopharmaceutical Market: Scope and Trends

This report on the radiopharmaceutical market analyzes the current and future scenario of the global market. Increase in incidence of various diseases, development of new sources for radioisotope production, and rise in demand for nuclear medicine are boosting the radiopharmaceutical market. Increase in incidence of cancer and cardiovascular diseases, growth in awareness about effective use of radiopharmaceuticals, and rise in preference for SPECT and PET scans are some of the factors expected to drive the growth of the global radiopharmaceutical market during the forecast period.

The radiopharmaceutical market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on radioisotopes, source, end-user, and geography. A detailed qualitative analysis of drivers and restraints, and opportunities has been provided in the market overview section. Additionally, the section comprises Porters Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global radiopharmaceutical market.

Radiopharmaceutical Market: Segmentation

Based on radioisotope, the market has been segmented into Technetium-99, Lutetium-177, Rubidium-87, Iodine-123, Yttrium-90, and Gallium-62. Technetium-99 is the most widely used radioisotope across the globe; around 70% of radiopharmaceutical companies depend on Mo-99 to produce Technetium-99, as per the World Nuclear Association. The market segments have been analyzed based on available approved products, cost-effectiveness, and preference for technological systems by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2017 to 2024, considering 2016 as the base year.

Based on source, the radiopharmaceutical market has been segmented into two major categories: nuclear reactors and cyclotrons. The market segments have been extensively analyzed based on increase in demand for radioisotopes for nuclear medicines, availability of radioisotopes and raw materials, radioisotopes short half-life and number of production units used for production of radioisotopes. Different types of end-user utilize radiopharmaceutical products to treat diseases either through imaging techniques or the therapeutics method.

Under the end-user segment, hospitals plays a major role followed by ambulatory surgical centers, diagnostic centers, and others (such as universities, research laboratories, and pathology labs). The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2014 to 2024. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2024, considering 2016 as the base year. Application segment signifies the usage of radiopharmaceutical products through different disease indication such as oncology, cardiology, neurology, nephrology, gastroenterology, immunology and others. Oncology segment is the dominant sector which emphasizes the use of different radioisotopes for treating various cancers and overcome the side effects of therapeutics. Brachytherapy is a sub segment of oncology application which signifies the methods of treating cancer through implants, surgery or radiation technology. The segment is expected to have a significant growth during the forecast period.

Geographically, the global radiopharmaceutical market has been categorized into five major regions and the key countries in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, Japan, China, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, Saudi Arabia, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2017 to 2024, considering 2016 as the base year.

Radiopharmaceutical Market: Competitive Landscape

The report also profiles major players in the global radiopharmaceutical market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Advanced Accelerator Applications (AAA), Eckert & Ziegler, GE Healthcare, IBA Radiopharma Solutions, Lantheus Holdings, Inc., Mallinckrodt PLC, Nordion, Inc., Siemens Healthineers, and Positron Corporation.

Key Segments of the Global Radiopharmaceuticals Market

By Radioisotope

  • Technetium-99
  • Gallium-67
  • Iodine-123
  • 18F
  • Rubidium-82
  • Yttrium-90
  • Lutetium-177

By Source

  • Nuclear Reactors
  • Cyclotrons

By End-user

  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Others

By Application

  • Cardiology
  • Gastroenterology
  • Oncology
  • Brachytherapy
  • Others
  • Nephrology
  • Neurology
  • Immunology
  • Others

By Region and Country

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Radiopharmaceutical Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Radioisotopes Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Key Market Indicators
  • 4.4. Market Dynamics
    • 4.4.1. Drivers
    • 4.4.2. Restraints
    • 4.4.3. Opportunity
  • 4.5. Global Radiopharmaceutical Market Analysis and Forecasts, 2014-2024
    • 4.5.1. Market Revenue Projections (US$ Mn)
  • 4.7. Porter's Five Force Analysis
  • 4.8. Value Chain Analysis
  • 4.9. Market Outlook
    • 4.9.1. FDA Approved Radiopharmaceutical Products, By Manufacturers & Trade Name
    • 4.9.2. Market Size (US$ Mn) & Forecast, 2014-2024
    • 4.9.3. Market Share (%), By Segments, 2016
    • 4.9.4. Global Supply Demand Scenario, By Country, 2015
  • 4.10. Application of Radiopharmaceutical (Peptide Receptor Radionuclide Therapy (PRRT) and Brachytherapy

5. Global Radiopharmaceutical Market Analysis and Forecasts, By Radioisotopes

  • 5.1. Introduction & Definition
  • 5.2. Key Findings / Developments
  • 5.3. Key Trends
  • 5.4. Market Value Analysis Forecast By Radioisotopes , 2014-2024
    • 5.4.1. Technetium-99
    • 5.4.2. Gallium-67
    • 5.4.3. Iodine-123
    • 5.4.4. Iodine-125
    • 5.4.5. 18F
    • 5.4.6. Rubidium-82
    • 5.4.7. Yttrium-90
    • 5.4.8. Lutetium-177
    • 5.4.9. Others
  • 5.5. Radioisotopes Comparison Matrix
  • 5.6. Market Attractiveness By Radioisotopes

6. Global Radiopharmaceutical Market Analysis and Forecasts, By Source

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Key Trends
  • 6.4. Market Value Analysis Forecast By Source , 2014-2024
    • 6.4.1. Nuclear Reactors
    • 6.4.2. Cyclotrons
  • 6.5. Source Comparison Matrix
  • 6.6. Market Attractiveness By Source

7. Global Radiopharmaceutical Market Analysis and Forecasts, By End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Key Trends
  • 7.4. Market Value Analysis Forecast By Application , 2014-2024
    • 7.4.1. Cardiology
    • 7.4.2. Gastroenterology
    • 7.4.3. Oncology
      • 7.4.3.1. Brachytherapy
      • 7.4.3.2. Others
    • 7.4.4. Nephrology
    • 7.4.5. Neurology
    • 7.4.6. Immunology
    • 7.4.7. Others
  • 7.5. End-user Comparison Matrix
  • 7.6. Market Attractiveness By End-user

8. Global Radiopharmaceutical Market Analysis and Forecasts, By End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Key Trends
  • 8.4. Market Value Analysis Forecast By End-user , 2014-2024
    • 8.4.1. Hospitals
    • 8.4.2. Ambulatory Surgical Centers
    • 8.4.3. Diagnostic Centers
    • 8.4.4. Cancer Research Institutes
    • 8.4.5. Others
  • 8.5. End-user Comparison Matrix
  • 8.6. Market Attractiveness By End-user

9. Global Radiopharmaceutical Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Policies and Regulations
  • 9.3. Market Value Analysis Forecast By Region
    • 9.3.1. North America
    • 9.3.2. Europe
    • 9.3.3. Asia Pacific
    • 9.3.4. Latin America
    • 9.3.5. Middle East and Africa
  • 9.4. Market Attractiveness By Country/Region

10. North America Radiopharmaceutical Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
    • 10.1.2. Policies and Regulations
  • 10.2. Market Value Analysis Forecast By Radioisotopes , 2014-2024
    • 10.2.1. Technetium-99
    • 10.2.2. Gallium-67
    • 10.2.3. Iodine-123
    • 10.2.4. Iodine-125
    • 10.2.5. 18F
    • 10.2.6. Rubidium-82
    • 10.2.7. Yttrium-90
    • 10.2.8. Lutetium-177
    • 10.2.9. Others
  • 10.3. Market Value Analysis Forecast By Source , 2014-2024
    • 10.3.1. Nuclear Reactors
    • 10.3.2. Cyclotrons
  • 10.4. Market Value Analysis Forecast By Application , 2014-2024
    • 10.4.1. Cardiology
    • 10.4.2. Gastroenterology
    • 10.4.3. Oncology
      • 10.4.3.1. Brachytherapy
      • 10.4.3.2. Others
    • 10.4.4. Nephrology
    • 10.4.5. Neurology
    • 10.4.6. Immunology
    • 10.4.7. Others
  • 10.5. Market Value Analysis Forecast By End-user , 2014-2024
    • 10.5.1. Hospitals
    • 10.5.2. Ambulatory Surgical Centers
    • 10.5.3. Diagnostic Centers
    • 10.5.4. Cancer Research Institutes
    • 10.5.5. Others
  • 10.6. Market Value Analysis Forecast By Country , 2014-2024
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Radioisotopes
    • 10.7.2. By Source
    • 10.7.3. By End-user
    • 10.7.4. By End-user
    • 10.7.5. By Country

11. Europe Radiopharmaceutical Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
    • 11.1.2. Policies and Regulations
  • 11.2. Market Value Analysis Forecast By Radioisotopes , 2014-2024
    • 11.2.1. Technetium-99
    • 11.2.2. Gallium-67
    • 11.2.3. Iodine-123
    • 11.2.4. Iodine-125
    • 11.2.5. 18F
    • 11.2.6. Rubidium-82
    • 11.2.7. Yttrium-90
    • 11.2.8. Lutetium-177
    • 11.2.9. Others
  • 11.3. Market Value Analysis Forecast By Source , 2014-2024
    • 11.3.1. Nuclear Reactors
    • 11.3.2. Cyclotrons
  • 11.4. Market Value Analysis Forecast By Application , 2014-2024
    • 11.4.1. Cardiology
    • 11.4.2. Gastroenterology
    • 11.4.3. Oncology
      • 11.4.3.1. Brachytherapy
      • 11.4.3.2. Others
    • 11.4.4. Nephrology
    • 11.4.5. Neurology
    • 11.4.6. Immunology
    • 11.4.7. Others
  • 11.5. Market Value Analysis Forecast By End-user , 2014-2024
    • 11.5.1. Hospitals
    • 11.5.2. Ambulatory Surgical Centers
    • 11.5.3. Diagnostic Centers
    • 11.5.4. Cancer Research Institutes
    • 11.5.5. Others
  • 11.6. Market Value Analysis Forecast By Country , 2014-2024
    • 11.6.1. U.K.
    • 11.6.2. Germany
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Radioisotopes
    • 11.7.2. By Source
    • 11.7.3. By End-user
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Asia Pacific Radiopharmaceutical Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
    • 12.1.2. Policies and Regulations
  • 12.2. Market Value Analysis Forecast By Radioisotopes , 2014-2024
    • 12.2.1. Technetium-99
    • 12.2.2. Gallium-67
    • 12.2.3. Iodine-123
    • 12.2.4. Iodine-125
    • 12.2.5. 18F
    • 12.2.6. Rubidium-82
    • 12.2.7. Yttrium-90
    • 12.2.8. Lutetium-177
    • 12.2.9. Others
  • 12.3. Market Value Analysis Forecast By Source , 2014-2024
    • 12.3.1. Nuclear Reactors
    • 12.3.2. Cyclotrons
  • 12.4. Market Value Analysis Forecast By Application , 2014-2024
    • 12.4.1. Cardiology
    • 12.4.2. Gastroenterology
    • 12.4.3. Oncology
      • 12.4.3.1. Brachytherapy
      • 12.4.3.2. Others
    • 12.4.4. Nephrology
    • 12.4.5. Neurology
    • 12.4.6. Immunology
    • 12.4.7. Others
  • 12.5. Market Value Analysis Forecast By End-user , 2014-2024
    • 12.5.1. Hospitals
    • 12.5.2. Ambulatory Surgical Centers
    • 12.5.3. Diagnostic Centers
    • 12.5.4. Cancer Research Institutes
    • 12.5.5. Others
  • 12.6. Market Value Analysis Forecast By Country , 2014-2024
    • 12.6.1. India
    • 12.6.2. China
    • 12.6.3. Japan
    • 12.6.4. Australia
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Radioisotopes
    • 12.7.2. By Source
    • 12.7.3. By End-user
    • 12.7.4. By End-user
    • 12.7.5. By Country

13. Latin America Radiopharmaceutical Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
    • 13.1.2. Policies and Regulations
  • 13.2. Market Value Analysis Forecast By Radioisotopes , 2014-2024
    • 13.2.1. Technetium-99
    • 13.2.2. Gallium-67
    • 13.2.3. Iodine-123
    • 13.2.4. Iodine-125
    • 13.2.5. 18F
    • 13.2.6. Rubidium-82
    • 13.2.7. Yttrium-90
    • 13.2.8. Lutetium-177
    • 13.2.9. Others
  • 13.3. Market Value Analysis Forecast By Source , 2014-2024
    • 13.3.1. Nuclear Reactors
    • 13.3.2. Cyclotrons
  • 13.4. Market Value Analysis Forecast By Application , 2014-2024
    • 13.4.1. Cardiology
    • 13.4.2. Gastroenterology
    • 13.4.3. Oncology
      • 13.4.3.1. Brachytherapy
      • 13.4.3.2. Others
    • 13.4.4. Nephrology
    • 13.4.5. Neurology
    • 13.4.6. Immunology
    • 13.4.7. Others
  • 13.5. Market Value Analysis Forecast By End-user , 2014-2024
    • 13.5.1. Hospitals
    • 13.5.2. Ambulatory Surgical Centers
    • 13.5.3. Diagnostic Centers
    • 13.5.4. Cancer Research Institutes
    • 13.5.5. Others
  • 13.6. Market Value Analysis Forecast By Country , 2014-2024
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Radioisotopes
    • 13.7.2. By Source
    • 13.7.3. By End-user
    • 13.7.4. By End-user
    • 13.7.5. By Country

14. Middle East and Africa Radiopharmaceutical Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
    • 14.1.2. Policies and Regulations
  • 14.2. Market Value Analysis Forecast By Radioisotopes , 2014-2024
    • 14.2.1. Technetium-99
    • 14.2.2. Gallium-67
    • 14.2.3. Iodine-123
    • 14.2.4. Iodine-125
    • 14.2.5. 18F
    • 14.2.6. Rubidium-82
    • 14.2.7. Yttrium-90
    • 14.2.8. Lutetium-177
    • 14.2.9. Others
  • 14.3. Market Value Analysis Forecast By Source , 2014-2024
    • 14.3.1. Nuclear Reactors
    • 14.3.2. Cyclotrons
  • 14.4. Market Value Analysis Forecast By Application , 2014-2024
    • 14.4.1. Cardiology
    • 14.4.2. Gastroenterology
    • 14.4.3. Oncology
      • 14.4.3.1. Brachytherapy
      • 14.4.3.2. Others
    • 14.4.4. Nephrology
    • 14.4.5. Neurology
    • 14.4.6. Immunology
    • 14.4.7. Others
  • 14.5. Market Value Analysis Forecast By End-user , 2014-2024
    • 14.5.1. Hospitals
    • 14.5.2. Ambulatory Surgical Centers
    • 14.5.3. Diagnostic Centers
    • 14.5.4. Cancer Research Institutes
    • 14.5.5. Others
  • 14.6. Market Value Analysis Forecast By Country , 2014-2024
    • 14.6.1. South Africa
    • 14.6.2. Saudi Arabia
    • 14.6.3. Rest of Middle East and Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Radioisotopes
    • 14.7.2. By Source
    • 14.7.3. By End-user
    • 14.7.4. By End-user
    • 14.7.5. By Country

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2015)
  • 15.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 15.3.1. Advanced Accelerator Applications (AAA)
      • 15.3.1.1. Overview
      • 15.3.1.2. Financials
      • 15.3.1.3. Recent Developments
      • 15.3.1.4. Strategy
    • 15.3.2. Bayer AG
      • 15.3.2.1. Overview
      • 15.3.2.2. Financials
      • 15.3.2.3. Recent Developments
      • 15.3.2.4. Strategy
    • 15.3.3. Eckert & Ziegler
      • 15.3.3.1. Overview
      • 15.3.3.2. Financials
      • 15.3.3.3. Recent Developments
      • 15.3.3.4. Strategy
    • 15.3.4. GE Healthcare
      • 15.3.4.1. Overview
      • 15.3.4.2. Financials
      • 15.3.4.3. Recent Developments
      • 15.3.4.4. Strategy
    • 15.3.5. IBA Radiopharma Solutions
      • 15.3.5.1. Overview
      • 15.3.5.2. Financials
      • 15.3.5.3. Recent Developments
      • 15.3.5.4. Strategy
    • 15.3.6. Lantheus Holdings, Inc.
      • 15.3.6.1. Overview
      • 15.3.6.2. Financials
      • 15.3.6.3. Recent Developments
      • 15.3.6.4. Strategy
    • 15.3.7. Mallinckrodt plc.
      • 15.3.7.1. Overview
      • 15.3.7.2. Financials
      • 15.3.7.3. Recent Developments
      • 15.3.7.4. Strategy
    • 15.3.8. Nordion, Inc.
      • 15.3.8.1. Overview
      • 15.3.8.2. Financials
      • 15.3.8.3. Recent Developments
      • 15.3.8.4. Strategy
    • 15.3.9. Positron Corporation
      • 15.3.9.1. Overview
      • 15.3.9.2. Financials
      • 15.3.9.3. Recent Developments
      • 15.3.9.4. Strategy
    • 15.3.10. Siemens Healthineers
      • 15.3.10.1. Overview
      • 15.3.10.2. Financials
      • 15.3.10.3. Recent Developments
      • 15.3.10.4. Strategy
Back to Top